Mild behavioral impairment as a potential marker of predementia risk states in motor neuron diseases.
amyotrophic lateral sclerosis
longitudinal cognitive decline
mild behavioral impairment
motor neuron diseases
prodromal dementia
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
19
07
2022
accepted:
09
09
2022
pubmed:
24
9
2022
medline:
17
12
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
Mild behavioral impairment (MBI) has been increasingly regarded as the neurobehavioral axis of predementia risk states, but a specific investigation of its detection as a potential marker of prodromal dementia in motor neuron diseases (MNDs) is still lacking. The aims of our study were therefore to explore MBI in MNDs both at onset and over the disease course, and to evaluate its relationship with baseline and longitudinal cognitive features. Sixty MND patients with cognitive/behavioral, mood, and motor examinations were recruited and followed longitudinally for up to 15 months. Associations between baseline MBI symptoms and clinical features were tested using the Spearman correlation coefficient. Based on longitudinal data, relative deltas of variation for each cognitive measure were generated, and linear regression models were then used to evaluate the role of baseline MBI symptoms in predicting longitudinal rates of cognitive decline. At disease onset, the most impaired MBI domain was affective/emotional dysregulation, followed by impulse dyscontrol, apathy, and social inappropriateness. Greater MBI symptoms correlated with more severe baseline motor, cognitive/behavioral, and mood disturbances (p values from <0.001 to 0.05). Longitudinally, the greatest decline was observed in the affective/emotional dysregulation domain, followed by impulse dyscontrol, apathy, and social inappropriateness. Greater MBI symptoms at onset were significant predictors of more severe longitudinal cognitive decline in both amyotrophic lateral sclerosis (ALS)-specific and ALS-nonspecific functions (p values from <0.001 to 0.03). MBI represents a valuable clinical marker of incident cognitive decline in MNDs, and its evaluation has good potential for detecting dementia in its preclinical/prodromal phase.
Sections du résumé
BACKGROUND AND PURPOSE
Mild behavioral impairment (MBI) has been increasingly regarded as the neurobehavioral axis of predementia risk states, but a specific investigation of its detection as a potential marker of prodromal dementia in motor neuron diseases (MNDs) is still lacking. The aims of our study were therefore to explore MBI in MNDs both at onset and over the disease course, and to evaluate its relationship with baseline and longitudinal cognitive features.
METHODS
Sixty MND patients with cognitive/behavioral, mood, and motor examinations were recruited and followed longitudinally for up to 15 months. Associations between baseline MBI symptoms and clinical features were tested using the Spearman correlation coefficient. Based on longitudinal data, relative deltas of variation for each cognitive measure were generated, and linear regression models were then used to evaluate the role of baseline MBI symptoms in predicting longitudinal rates of cognitive decline.
RESULTS
At disease onset, the most impaired MBI domain was affective/emotional dysregulation, followed by impulse dyscontrol, apathy, and social inappropriateness. Greater MBI symptoms correlated with more severe baseline motor, cognitive/behavioral, and mood disturbances (p values from <0.001 to 0.05). Longitudinally, the greatest decline was observed in the affective/emotional dysregulation domain, followed by impulse dyscontrol, apathy, and social inappropriateness. Greater MBI symptoms at onset were significant predictors of more severe longitudinal cognitive decline in both amyotrophic lateral sclerosis (ALS)-specific and ALS-nonspecific functions (p values from <0.001 to 0.03).
CONCLUSIONS
MBI represents a valuable clinical marker of incident cognitive decline in MNDs, and its evaluation has good potential for detecting dementia in its preclinical/prodromal phase.
Identifiants
pubmed: 36148819
doi: 10.1111/ene.15570
pmc: PMC10091712
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-56Informations de copyright
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Behav Neurol. 2013;27(2):143-53
pubmed: 23001631
Eur J Neurol. 2016 May;23(5):891-7
pubmed: 26822417
BMC Neurol. 2012 Dec 07;12:156
pubmed: 23216745
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):172-6
pubmed: 23421625
Brain. 2011 Dec;134(Pt 12):3458-69
pubmed: 22155983
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):202-209
pubmed: 28165766
Amyotroph Lateral Scler. 2007 Feb;8(1):56-61
pubmed: 17364437
Neurol Sci. 2017 Jun;38(6):1059-1068
pubmed: 28332040
Lancet Neurol. 2007 Nov;6(11):994-1003
pubmed: 17945153
Neurobiol Aging. 2013 Nov;34(11):2499-509
pubmed: 23806980
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):9-14
pubmed: 23781974
Psychogeriatrics. 2021 Jan;21(1):100-111
pubmed: 33260271
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):153-174
pubmed: 28054827
Eur J Neurol. 2010 Jan;17(1):103-10
pubmed: 19874396
Neurol Clin Pract. 2017 Dec;7(6):488-498
pubmed: 29431172
Neurology. 2018 Oct 9;91(15):e1370-e1380
pubmed: 30209236
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):489-498
pubmed: 27219526
Alzheimers Dement. 2016 Feb;12(2):195-202
pubmed: 26096665
J Neurol Sci. 2014 Oct 15;345(1-2):164-7
pubmed: 25086855
Am J Geriatr Psychiatry. 2020 Jul;28(7):755-763
pubmed: 31928846
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Neurology. 2019 Aug 20;93(8):e766-e777
pubmed: 31320470
Neurology. 2011 Apr 5;76(14):1263-9
pubmed: 21464431
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur J Neurol. 2023 Jan;30(1):47-56
pubmed: 36148819
Amyotroph Lateral Scler Frontotemporal Degener. 2020 Aug;21(5-6):373-379
pubmed: 32484726
Neurology. 2005 Jul 12;65(1):62-7
pubmed: 16009886
J Alzheimers Dis. 2018;62(1):227-238
pubmed: 29439333
J Alzheimers Dis. 2021;80(1):459-469
pubmed: 33554909
J Neurol. 2007 Apr;254(4):519-27
pubmed: 17401515
Amyotroph Lateral Scler. 2008 Apr;9(2):67-74
pubmed: 18427998
J Alzheimers Dis. 2017;56(3):929-938
pubmed: 28059789
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):675-680
pubmed: 28596248
Neurol Sci. 2011 Feb;32(1):9-16
pubmed: 20953810
Front Neurosci. 2019 Sep 10;13:951
pubmed: 31551700
Br J Gen Pract. 2009 Sep;59(566):e283-8
pubmed: 19761655
Am J Geriatr Psychiatry. 2019 Aug;27(8):823-834
pubmed: 30902566
Amyotroph Lateral Scler Frontotemporal Degener. 2021 Feb;22(1-2):66-72
pubmed: 32757854
Behav Neurol. 2018 Oct 31;2018:5969137
pubmed: 30515252
Int Psychogeriatr. 2020 Jun;32(6):705-717
pubmed: 31526407
Amyotroph Lateral Scler. 2011 Jan;12(1):45-51
pubmed: 20849323
Neurology. 1999 Nov 10;53(8):1665-70
pubmed: 10563610
Riv Psichiatr. 2019 Mar-Apr;54(2):59-66
pubmed: 30985830
Behav Neurol. 2014;2014:230578
pubmed: 25161339
J Neurol Sci. 2017 May 15;376:16-23
pubmed: 28431606
Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23
pubmed: 19922118
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):740-6
pubmed: 21402743
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):387-395
pubmed: 29804470
J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):168-73
pubmed: 24769471